CLINICAL TRIALS PROFILE FOR REMODULIN

All Clinical Trials for REMODULIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00058929 ↗	A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension	Completed	United Therapeutics	Phase 4	2002-10-01	This trial is a study of Remodulin in patients with pulmonary arterial hypertension who have been transitioned from Flolan therapy. The study consists of Screening, Baseline and Treatment Phases. Patients meeting all inclusion/exclusion criteria during the Screening Phase will enter the Baseline Phase, during which baseline exercise capacity, vital signs, and clinical signs and symptoms of the disease will be assessed. After confirmation of all inclusion/exclusion criteria, patients will be assigned to study drug (Remodulin or placebo) and will enter the Treatment Phase. The Treatment Phase begins with a Dose Transition Period, during which patients will begin receiving subcutaneous study drug at a low dose determined by the patient's current dose of Flolan. The study drug dose will be increased gradually while the Flolan dose is decreased gradually over a period of up to 14 days. The dose changes will continue until Flolan therapy has been discontinued and the patient is stable on study drug. Patients who are transitioned off Flolan, who are stable on study drug will be discharged from the clinic, and will continue to receive study drug on an outpatient basis. The patient will return to the clinic at Weeks 4 and 8 for assessments. Patients will remain on study drug for 8 weeks from the first dose of study drug. At Week 8, final assessments will be conducted and the patient will be dismissed from the study. Patients who successfully complete Week 8 assessments may be offered Remodulin therapy or other therapy, at the investigator's discretion.
NCT00060996 ↗	Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures	Terminated	United Therapeutics	Phase 3	2003-02-01	The purpose of this study is to assess and compare the safety of continuous and daily subcutaneous Remodulin therapy in patients with critical limb ischemia (CLI) with no planned vascular interventional procedures; and to determine the effect of Remodulin on wound healing and treadmill walk distance.
NCT00067041 ↗	Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft	Terminated	United Therapeutics	Phase 2/Phase 3	2003-03-01	Approximately 30 patients will be enrolled in this 12-week study designed to assess the effect of continuous subcutaneous Remodulin therapy on the outcome of infrainguinal bypass grafts in patients with critical limb ischemia (CLI). Portions of the study will be conducted in the hospital and on an out-patient basis. The study will be conducted at multiple centers.

Clinical Trial Conditions for REMODULIN

Condition Name

Condition Name for REMODULIN
Intervention	Trials
Pulmonary Arterial Hypertension	15
Pulmonary Hypertension	7
Hypertension, Pulmonary	2

Condition MeSH

Condition MeSH for REMODULIN
Intervention	Trials
Hypertension	23
Pulmonary Arterial Hypertension	18
Familial Primary Pulmonary Hypertension	17

Clinical Trial Locations for REMODULIN

Trials by Country

Trials by Country for REMODULIN
Location	Trials
United States	78
China	2
United Kingdom	1
Egypt	1
India	1

Trials by US State

Trials by US State for REMODULIN
Location	Trials
California	10
Ohio	7
Massachusetts	6
New York	5
Pennsylvania	5

Clinical Trial Progress for REMODULIN

Clinical Trial Phase

Clinical Trial Phase for REMODULIN
Clinical Trial Phase	Trials
Phase 4	13
Phase 3	3
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for REMODULIN
Clinical Trial Phase	Trials
Completed	12
Terminated	6
Withdrawn	5

Clinical Trial Sponsors for REMODULIN

Sponsor Name

Sponsor Name for REMODULIN
Sponsor	Trials
United Therapeutics	23
University of California, Los Angeles	3
CVie Therapeutics Co. Ltd.	2

Sponsor Type

Sponsor Type for REMODULIN
Sponsor	Trials
Industry	27
Other	23

Remodulin (Treprostinil): Clinical Trials Update, Market Analysis, and Projections

Last updated: January 27, 2026

Executive Summary

Remodulin (treprostinil), developed by United Therapeutics, is a prostacyclin analogue indicated primarily for pulmonary arterial hypertension (PAH). This comprehensive report evaluates recent clinical trial developments, analyzes the current market landscape, and projects future market growth based on ongoing research, approval trends, and market dynamics.

Key insights include:

• Robust pipeline and recent clinical trial results supporting remodulin's efficacy.
• Competitive positioning against agents like epoprostenol, iloprost, and newer oral therapies.
• Market valuation estimated at USD 1.2 billion in 2022, with projected CAGR of 7.2% (2023–2028).
• Factors influencing growth include increasing PAH diagnosis rates, expanding indications, and pipeline innovations.

---

1. Clinical Trials Update

Recent and Ongoing Trials

Trial Name	Phase	Focus	Status	Key Outcomes/Details	References
FREEDOM-C	III	Oral treprostinil in PAH	Completed	Demonstrated non-inferiority to IV infusions in functional capacity	[1]
FREEDOM-E	III	Escalation and combination strategies	Ongoing	Evaluating oral treprostinil with other therapies	[2]
PGI2 (Prostacyclin) Alternative Studies	II/III	Inhaled and subcutaneous routes	Ongoing	Aiming to improve patient adherence and reduce complications	[3]

Key Recent Results

• FREEDOM-C Study (2021): Oral treprostinil achieved significant improvements in 6-minute walk distance (6MWD) compared to placebo (mean difference: 25 meters, p<0.05). The tolerability profile remained consistent with previous data.
• Extension and Combination Trials: Early data suggest synergistic benefits when combined with endothelin receptor antagonists and phosphodiesterase-5 inhibitors, indicating favorable prospects for combination therapy strategies.

Regulatory Milestones

• FDA approval for IV and subcutaneous remodulin remains unchanged since 2002; however, oral formulations are under active investigation to enhance patient convenience.
• EMA and other agencies are reviewing supplemental data for expanded indications, especially in pediatric populations and early-stage PAH.

---

2. Market Analysis

Current Market Size and Segments

Parameter	Details
Global Market Size (2022)	USD 1.2 billion
Key Geographies	North America (57%), Europe (25%), Asia-Pacific (10%), Others (8%)
Distribution by Administration Route	IV (45%), Subcutaneous (30%), Oral (15%), Inhaled (10%)

Competitive Landscape

Drug / Therapy	Type	Approval Year	Market Share (2022)	Notes
Remodulin (treprostinil)	Prostacyclin analogue	2002 (IV/subQ)	38%	Leading injectable prostacyclin agent
Flolan (epoprostenol)	Prostacyclin	1995	30%	Mostly IV; high stability but invasive
Tyvaso (treprostinil inhalation)	Inhaled treprostinil	2014	12%	Less invasive, improving adherence
Opsumit (macitentan)	Endothelin receptor antagonist	2013	10%	Oral therapy, broader market penetration
Adempas (riociguat)	Soluble guanylate cyclase stimulator	2013	5%	Alternative pathway targeting

Market Drivers

• Increased diagnosed PAH cases (estimated at 4,000–6,000 annually in the U.S.).
• Approval of new formulations (oral treprostinil) offers easier administration.
• Expansion of indications to connective tissue disease-associated PAH.
• Continued pipeline progress reduces the impact of existing competitors.

Market Challenges

• High cost of prostacyclin therapies.
• Invasive administration routes decreasing patient adherence.
• Competition from oral agents with simpler regimens.
• Safety profiles of prostacyclins require careful management.

Regulatory and Policy Trends

• Emphasis on oral therapies driven by patient preference and outpatient management.
• Payer pressure to demonstrate cost-effectiveness.
• Reimbursement policies favoring early initiation of combination therapies.

---

3. Market Projection (2023–2028)

Parameter	2023	2024	2025	2026	2027	2028
Market Size (USD billion)	1.27	1.37	1.47	1.59	1.71	1.84
CAGR (2023–2028)	—	7.2%	7.1%	7.0%	6.9%	6.8%

Forecast Assumptions

• Pipeline Success: Ongoing trials leading to increased approvals, especially for oral and inhaled treprostinil.
• Indication Expansion: Broader use in pediatric and early-stage PAH.
• Market Penetration: Oral formulations capturing ≥20% of the market by 2028.
• Pricing Trends: Slight rise, offset by increased competition and payer negotiations.

Key Growth Catalysts

• Development of oral treprostinil, reducing administration barriers.
• Global access expansion into emerging markets.
• Innovations improving safety and tolerability.
• Growth in combination therapy adoption.

---

4. Comparative Analysis and Strategic Insights

Factor	Remodulin	Epoprostenol (Flolan)	Iloprost	Oral Treprostinil (FREEDOM Studies)
Route of Administration	IV/subQ	IV	Inhaled	Oral / IV / SubQ
Onset of Action	Rapid	Rapid	Moderate	Moderate
Patient Convenience	Low	Low	High	High
Market Penetration	Strong	Established	Moderate	Growing
Pipeline Stage	Mature	Mature	Mature	Active (phase III)

Strategic Considerations:

• Remodulin’s established efficacy continues to position it as a standard treatment, with growth potential rooted in new formulations.
• Oral treprostinil's developmental progress suggests a shift toward less invasive options.
• Competitive advantage hinges on safety, tolerability, and patient adherence improvements.

---

5. Frequently Asked Questions (FAQs)

Q1: What are the main clinical advantages of Remodulin compared to other PAH therapies?

A: Remodulin's advantages include its potent vasodilatory effects, rapid onset, and established efficacy in improving exercise capacity and delaying disease progression. Its subcutaneous and intravenous routes allow direct systemic delivery, though invasive, with consistent plasma levels. New oral formulations aim to replicate these benefits with improved convenience.

Q2: How does the ongoing pipeline impact Remodulin's market position?

A: The pipeline, notably oral treprostinil (e.g., FREEDOM-E), aims to provide effective non-invasive options, potentially reducing reliance on injectable forms. Success of these trials could shift market dynamics, possibly reducing Remodulin's dominance unless it complements new therapies.

Q3: What are the primary safety concerns associated with Remodulin?

A: Common adverse events include infusion site pain, hypotension, headache, jaw pain, diarrhea, and flushing. Serious complications, such as catheter infections and hypotension-related events, require vigilant management.

Q4: What regulatory developments are anticipated for Remodulin in the next 5 years?

A: Expect potential approval of oral treprostinil formulations, expanded indications in pediatric populations, and possible approval for early intervention strategies, driven by ongoing trial results and regulatory submissions.

Q5: How is the market expected to evolve regarding administration routes?

A: There is a marked shift toward oral and inhaled therapies, with oral treprostinil expected to capture a significant market share due to its convenience, potentially supplanting some injectable therapies like Remodulin, especially as new delivery systems improve tolerability.

---

Key Takeaways

• Robust Clinical Data: Recent and ongoing trials consistently affirm Remodulin’s efficacy in PAH, with a focus on optimizing safety and tolerability.
• Market Leadership: Despite competition, Remodulin maintains a sizable share due to its proven effectiveness. Future growth depends on the successful commercialization of oral formulations.
• Pipeline Impact: The advancement of oral treprostinil and inhaled variants will influence Remodulin’s market share; however, its role remains pivotal in severe or refractory cases.
• Growth Drivers: Increase in PAH diagnosis, earlier intervention, combination therapy strategies, and patient preference for less invasive options underpin projected growth.
• Challenges: High treatment costs, administration complexity, and competition from oral drugs pose ongoing hurdles.

---

References

[1] FREEDOM-C Trial Data, United Therapeutics, 2021.
[2] FREEDOM-E Trial Protocol, United Therapeutics, 2022.
[3] Current Clinical Trials Database, ClinicalTrials.gov, accessed January 2023.
[4] Market Research: Pulmonary Hypertension Drugs Market Size & Forecast, 2022–2028.
[5] Regulatory Filings and Approvals, FDA and EMA, 2022–2023.